Dong Hua
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Dong Hua has a total of 175 co-authors. Here are the top co-authors by number of shared publications:
- Yong Mao
Department of Oncology, Affiliated Hospital of Jiangnan University, Wuxi, China
8 shared publications Fang Wang
Department of Public Health and Preventive Medicine, Jiangnan University School of Wuxi Medicine, Wuxi, China
7 shared publicationsXiaowei Qi
Department of Oncology, Affiliated Hospital of Jiangnan University, Wuxi, China
6 shared publicationsYong Mao
Department of Oncology, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu Province, China
6 shared publicationsShuai Liang
Department of Radiation Oncology, Weifang People's Hospital, Shandong Second Medical University, China
5 shared publicationsTeng Wang
Department of Oncology, Affiliated Hospital of Jiangnan University, Wuxi 214062, Jiangsu Province, China
5 shared publications
Latest Publications
- Open Access
- 27 May 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (6) , e71772
FKBP9 Enhances Colon Cancer Cell Proliferation by Inhibiting GPX4 ‐Mediated Ferroptosis
Colorectal cancer, a major health issue worldwide, exhibits intricate molecular mechanisms that necessitate further exploration, particularly regarding regulated cell death pathways, such as ferroptosis. This study investigated the role of the immunophilin FKBP9 (FK506 Binding Protein 9) in colon cancer, specifically its effects on cell proliferation and ferroptosis resistance. Using molecular biology techniques, including quantitative reverse transcription PCR, Western blotting, and cell proliferation assays, we established that FKBP9 is overexpressed in colon cancer cell lines HCT116 and SW480. Furthermore, we demonstrated that FKBP9 enhances cell proliferation by inhibiting ferroptosis through glutathione peroxidase 4 (GPX4) expression upregulation, thereby reducing reactive oxygen species levels and stabilizing GPX4 by preventing its autophagic degradation. Notably, increased FKBP9 expression is associated with lower overall survival rates in patients with colon cancer, suggesting its potential as a prognostic marker. These findings underscore the therapeutic potential of FKBP9 in colon cancer, offering a new method to sensitize cancer cells to ferroptosis and improve patient outcomes.
- 27 May 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (6) , e71772
Open AccessFKBP9 Enhances Colon Cancer Cell Proliferation by Inhibiting GPX4 ‐Mediated Ferroptosis
Colorectal cancer, a major health issue worldwide, exhibits intricate molecular mechanisms that necessitate further exploration, particularly regarding regulated cell death pathways, such as ferroptosis. This study investigated the role of the immunophilin FKBP9 (FK506 Binding Protein 9) in colon cancer, specifically its effects on cell proliferation and ferroptosis resistance. Using molecular biology techniques, including quantitative reverse transcription PCR, Western blotting, and cell proliferation assays, we established that FKBP9 is overexpressed in colon cancer cell lines HCT116 and SW480. Furthermore, we demonstrated that FKBP9 enhances cell proliferation by inhibiting ferroptosis through glutathione peroxidase 4 (GPX4) expression upregulation, thereby reducing reactive oxygen species levels and stabilizing GPX4 by preventing its autophagic degradation. Notably, increased FKBP9 expression is associated with lower overall survival rates in patients with colon cancer, suggesting its potential as a prognostic marker. These findings underscore the therapeutic potential of FKBP9 in colon cancer, offering a new method to sensitize cancer cells to ferroptosis and improve patient outcomes.
- 18 December 2025
- Published by Elsevier in Journal of Colloid and Interface Science
- Vol. 707, 139717
Promoting endogenous iron mediated ferroptosis for cancer therapy through gene interference and reactive oxygen species amplification
- 18 December 2025
- Published by Elsevier in Journal of Colloid and Interface Science
- Vol. 707, 139717
Promoting endogenous iron mediated ferroptosis for cancer therapy through gene interference and reactive oxygen species amplification
- Open Access
- 1 December 2025
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 14 (12) , 8404-8417
Upregulation of spondin-2 indicates poorer clinical outcomes and induces radioresistance in gastric cancer
Background: Spondin-2 (SPON2) has been reported to be upregulated in various carcinomas, contributing to cancer progression and metastasis. However, its underlying mechanism in gastric cancer (GC) remains poorly understood. This study aimed to explore the relationship between SPON2 expression, prognostic outcomes, and radiotherapy sensitivity in GC. Methods: Public datasets from the cBioPortal website were used to assess SPON2 expression in GC tissues and its clinical significance. The regulatory role of SPON2 in the cell cycle, apoptosis, DNA damage repair (DDR), proliferation, and migration was investigated using the GC cell line HGC-27 under conditions with or without radiation. Results: SPON2 expression in GC tissues was significantly higher than in normal gastric tissues (PConclusions: Upregulated SPON2 promotes GC cell proliferation and is associated with poorer OS in patients with GC. SPON2 overexpression induces cellular resistance to radiation, decreasing radiation-induced DNA damage and apoptosis. Therefore, SPON2 may serve as a potential predictor of radiotherapy efficacy and poor prognosis in GC.
- 1 December 2025
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 14 (12) , 8404-8417
Open AccessUpregulation of spondin-2 indicates poorer clinical outcomes and induces radioresistance in gastric cancer
Background: Spondin-2 (SPON2) has been reported to be upregulated in various carcinomas, contributing to cancer progression and metastasis. However, its underlying mechanism in gastric cancer (GC) remains poorly understood. This study aimed to explore the relationship between SPON2 expression, prognostic outcomes, and radiotherapy sensitivity in GC. Methods: Public datasets from the cBioPortal website were used to assess SPON2 expression in GC tissues and its clinical significance. The regulatory role of SPON2 in the cell cycle, apoptosis, DNA damage repair (DDR), proliferation, and migration was investigated using the GC cell line HGC-27 under conditions with or without radiation. Results: SPON2 expression in GC tissues was significantly higher than in normal gastric tissues (PConclusions: Upregulated SPON2 promotes GC cell proliferation and is associated with poorer OS in patients with GC. SPON2 overexpression induces cellular resistance to radiation, decreasing radiation-induced DNA damage and apoptosis. Therefore, SPON2 may serve as a potential predictor of radiotherapy efficacy and poor prognosis in GC.
- 23 September 2025
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 216, 104963
Artificial intelligence enabled tumor diagnosis and treatment: Status, breakthroughs and challenges
- 23 September 2025
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 216, 104963
Artificial intelligence enabled tumor diagnosis and treatment: Status, breakthroughs and challenges
- Open Access
- 16 September 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1648432
Bridging the gap: ferroptosis of immune cells in the tumor microenvironment
Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, is increasingly recognized as a pivotal immunomodulatory mechanism within the tumor microenvironment (TME). Beyond its well-established role in tumor cell elimination, emerging evidence reveals that immune cell subsets exhibit distinct susceptibility to ferroptosis, with profound consequences for antitumor immunity. This review systematically delineates the dual and cell-type-specific roles of ferroptosis across innate and adaptive immune populations: while ferroptosis-mediated depletion of immunosuppressive cells potentiates antitumor responses, immunostimulatory cells critically depend on ferroptosis defense pathways to sustain their survival and function—their dysfunction exacerbates immune evasion. We further decode the metabolic and signaling networks that govern immune cell ferroptosis and their dynamic interplay with immunotherapy and engineered nanomaterials. Finally, we critically addressed key challenges in clinical translation, including biomarker development, cell-specific delivery, and design of nanomaterials to minimize off-target effects. By elucidating the immune context-dependence of ferroptosis, this review provides a framework for developing precision therapies that harness ferroptosis-immune crosstalk to improve cancer therapy in the clinic.
- 16 September 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1648432
Open AccessBridging the gap: ferroptosis of immune cells in the tumor microenvironment
Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, is increasingly recognized as a pivotal immunomodulatory mechanism within the tumor microenvironment (TME). Beyond its well-established role in tumor cell elimination, emerging evidence reveals that immune cell subsets exhibit distinct susceptibility to ferroptosis, with profound consequences for antitumor immunity. This review systematically delineates the dual and cell-type-specific roles of ferroptosis across innate and adaptive immune populations: while ferroptosis-mediated depletion of immunosuppressive cells potentiates antitumor responses, immunostimulatory cells critically depend on ferroptosis defense pathways to sustain their survival and function—their dysfunction exacerbates immune evasion. We further decode the metabolic and signaling networks that govern immune cell ferroptosis and their dynamic interplay with immunotherapy and engineered nanomaterials. Finally, we critically addressed key challenges in clinical translation, including biomarker development, cell-specific delivery, and design of nanomaterials to minimize off-target effects. By elucidating the immune context-dependence of ferroptosis, this review provides a framework for developing precision therapies that harness ferroptosis-immune crosstalk to improve cancer therapy in the clinic.
- 2 September 2025
- Published by Wiley in Chemnanomat
- Vol. 11 (12)
Engineering Aptamer‐Guided and Glutathione‐Depleted Metal–Organic Framework Nanoinducer for Cancer Dual Phototherapy
In emerging strategies for localized tumor therapy, FDA‐approved indocyanine green (ICG) is a promising candidate for phototherapy. Despite its potential, ICG's application is hindered by aqueous instability, intracellular antioxidant scavenging, and rapid clearance, necessitating nanomaterial‐based formulations. Herein, a multifunctional nanoplatform integrating ICG into a glutathione (GSH)‐responsive metal–organic framework (MOF) functionalized with AS1411 aptamers (AS1411@ICG@MOF, MIA) for stimuli‐responsive delivery and intracellular redox regulation is developed. Constructed with a GSH‐degradable MOF core for ICG encapsulation and an AS1411 aptamer shell for nucleolin targeting, MIA enables active tumor cell accumulation. Under laser irradiation, ICG acts as both a photosensitizer and photothermal agent, generating reactive oxygen species (ROS) and heat for synergistic photodynamic therapy/photothermal therapy (PDT/PTT). Thereout, GSH‐triggered MOF disintegration facilitates intracellular ICG release, overcoming bioavailability challenges and GSH‐mediated ROS consumption. Moreover, mild PTT minimizes off‐target thermal injury while enhancing PDT via GSH depletion. Taken together, through aptamer‐targeted delivery and GSH‐responsive degradation, MIA achieves spatiotemporal control of ROS amplification and mild PTT, offering a promising strategy for synergistic cancer therapy.
- 2 September 2025
- Published by Wiley in Chemnanomat
- Vol. 11 (12)
Engineering Aptamer‐Guided and Glutathione‐Depleted Metal–Organic Framework Nanoinducer for Cancer Dual Phototherapy
In emerging strategies for localized tumor therapy, FDA‐approved indocyanine green (ICG) is a promising candidate for phototherapy. Despite its potential, ICG's application is hindered by aqueous instability, intracellular antioxidant scavenging, and rapid clearance, necessitating nanomaterial‐based formulations. Herein, a multifunctional nanoplatform integrating ICG into a glutathione (GSH)‐responsive metal–organic framework (MOF) functionalized with AS1411 aptamers (AS1411@ICG@MOF, MIA) for stimuli‐responsive delivery and intracellular redox regulation is developed. Constructed with a GSH‐degradable MOF core for ICG encapsulation and an AS1411 aptamer shell for nucleolin targeting, MIA enables active tumor cell accumulation. Under laser irradiation, ICG acts as both a photosensitizer and photothermal agent, generating reactive oxygen species (ROS) and heat for synergistic photodynamic therapy/photothermal therapy (PDT/PTT). Thereout, GSH‐triggered MOF disintegration facilitates intracellular ICG release, overcoming bioavailability challenges and GSH‐mediated ROS consumption. Moreover, mild PTT minimizes off‐target thermal injury while enhancing PDT via GSH depletion. Taken together, through aptamer‐targeted delivery and GSH‐responsive degradation, MIA achieves spatiotemporal control of ROS amplification and mild PTT, offering a promising strategy for synergistic cancer therapy.
- 30 October 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 143 (Pt 2) , 113482
From darkness to light: Targeting CAFs as a new potential strategy for cancer treatment
- 30 October 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 143 (Pt 2) , 113482
From darkness to light: Targeting CAFs as a new potential strategy for cancer treatment
- 3 June 2024
- Published by Royal Society of Chemistry (RSC) in Analytical Methods
- Vol. 16 (24) , 3878-3894
A novel SERS-lateral flow assay (LFA) tray for monitoring of miR-155-5p during pyroptosis in breast cancer cells
Upon addition of cell lysates to the sample pad, SERS probes located on the conjugation pad would bind to target miRNAs, leading to no captured SERS probes and no discernible color change on the T line.
- 3 June 2024
- Published by Royal Society of Chemistry (RSC) in Analytical Methods
- Vol. 16 (24) , 3878-3894
A novel SERS-lateral flow assay (LFA) tray for monitoring of miR-155-5p during pyroptosis in breast cancer cells
Upon addition of cell lysates to the sample pad, SERS probes located on the conjugation pad would bind to target miRNAs, leading to no captured SERS probes and no discernible color change on the T line.
- Open Access
- 25 April 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (8) , e7208
Prognostic implications of combining EGFR‐TKIs and radiotherapy in Stage IV lung adenocarcinoma with 19‐Del or 21‐L858R mutations: A real‐world study
Objective: To elucidate the potential benefits of combining radiotherapy and epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) for individuals with Stage IV lung adenocarcinoma (LUAD) harboring either exon 19 deletion (19‐Del) or exon 21 L858R mutation (21‐L858R).Methods: In this real‐world retrospective study, 177 individuals with Stage IV LUAD who underwent EGFR‐TKIs and radiotherapy at Shandong Cancer Hospital from June 2012 to August 2017 were included. The main focus of this real‐world study was overall survival (OS).Results: The clinical characteristics of patients with Stage IV LUAD harboring 19‐Del were similar to those harboring 21‐L858R (p > 0.05). Overall, the patients had a median OS (mOS) of 32.0 months (95% confidence interval [CI]: 28.6–35.5). Subsequently, multivariate analysis indicated that both EGFR mutations and thoracic radiotherapy were independent predictors of OS (p = 0.001 and 0.013). Furthermore, subgroup analysis highlighted a longer OS for the 19‐Del group compared to the 21‐L858R group, especially when EGFR‐TKIs were combined with bone metastasis or thoracic radiotherapy (mOS: 34.7 vs. 25.1 months and 51.0 vs. 29.6 months; p = 0.0056 and 0.0013, respectively). However, no significant differences were found in OS when considering patients who underwent brain metastasis radiotherapy (mOS: 34.7 vs. 25.1 months; p = 0.088).Conclusions: Patients with Stage IV LUAD harboring 19‐Del experience a notably prolonged OS following combined therapy with EGFR‐TKIs and radiotherapy, while this OS benefit is observed despite the absence of substantial differences in the clinical characteristics between the 19‐Del and 21‐L858R groups.
- 25 April 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (8) , e7208
Open AccessPrognostic implications of combining EGFR‐TKIs and radiotherapy in Stage IV lung adenocarcinoma with 19‐Del or 21‐L858R mutations: A real‐world study
Objective: To elucidate the potential benefits of combining radiotherapy and epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) for individuals with Stage IV lung adenocarcinoma (LUAD) harboring either exon 19 deletion (19‐Del) or exon 21 L858R mutation (21‐L858R).Methods: In this real‐world retrospective study, 177 individuals with Stage IV LUAD who underwent EGFR‐TKIs and radiotherapy at Shandong Cancer Hospital from June 2012 to August 2017 were included. The main focus of this real‐world study was overall survival (OS).Results: The clinical characteristics of patients with Stage IV LUAD harboring 19‐Del were similar to those harboring 21‐L858R (p > 0.05). Overall, the patients had a median OS (mOS) of 32.0 months (95% confidence interval [CI]: 28.6–35.5). Subsequently, multivariate analysis indicated that both EGFR mutations and thoracic radiotherapy were independent predictors of OS (p = 0.001 and 0.013). Furthermore, subgroup analysis highlighted a longer OS for the 19‐Del group compared to the 21‐L858R group, especially when EGFR‐TKIs were combined with bone metastasis or thoracic radiotherapy (mOS: 34.7 vs. 25.1 months and 51.0 vs. 29.6 months; p = 0.0056 and 0.0013, respectively). However, no significant differences were found in OS when considering patients who underwent brain metastasis radiotherapy (mOS: 34.7 vs. 25.1 months; p = 0.088).Conclusions: Patients with Stage IV LUAD harboring 19‐Del experience a notably prolonged OS following combined therapy with EGFR‐TKIs and radiotherapy, while this OS benefit is observed despite the absence of substantial differences in the clinical characteristics between the 19‐Del and 21‐L858R groups.
- Open Access
- 15 November 2023
- Published by CMB Association in Cellular and Molecular Biology
- Vol. 69 (11) , 132-140
HDAC1 suppresses radiotherapy sensitivity in cervical cancer via regulating HIF-1α/VEGF signaling pathway
Cervical cancer (CC) is the fourth most common cancer amongst females worldwide. Histone deacetylase (HDAC) 1 plays a vital role in several tumors. Nevertheless, its potential and mechanism in radiotherapy sensitivity underlying CC remains obscure. Hence, the objective of this research was to probe the potential of HDAC1 in CC radiotherapy sensitivity and its mechanism of action. The expression HDACs and survival analysis of HDAC1 were investigated based on the GEPIA database. Immunohistochemical staining was implemented to detect HDAC1 and Ki-67 expression in tumor tissues. RT-qPCR and Western blot were conducted to assess HDAC1, HIF-1α, VEGFA, along with VEGFR expressions in CC cells and tumor tissues. Cell viability, apoptosis, invasion, migration, along with cell cycle were analyzed by functional assays. Tumor-bearing nude mice model was established, and the tumor weight and volume were determined. HDAC1 was high-expressed in the tumor tissue and CC cells. In vitro, overexpression of HDAC1 suppressed radiotherapy sensitivity in C33A cells, while knockdown of HDAC1 promoted radiotherapy sensitivity in SiHa cells. In vivo, we found that HDAC1 silence hindered tumor growth and cell proliferation and promoted tumor cell apoptosis in nude mice after radiotherapy. In addition, we found that HDAC1 impacted radiotherapy sensitivity by modulating the HIF-1α/VEGF signaling pathway. In conclusion, HDAC1 suppressed the radiotherapy sensitivity of CC via regulating HIF-1α/VEGF signaling pathway, suggesting that HDAC1 may act as a crucial participant in regulating CC radiosensitivity, which may provide a novel method for treating CC.
- 15 November 2023
- Published by CMB Association in Cellular and Molecular Biology
- Vol. 69 (11) , 132-140
Open AccessHDAC1 suppresses radiotherapy sensitivity in cervical cancer via regulating HIF-1α/VEGF signaling pathway
Cervical cancer (CC) is the fourth most common cancer amongst females worldwide. Histone deacetylase (HDAC) 1 plays a vital role in several tumors. Nevertheless, its potential and mechanism in radiotherapy sensitivity underlying CC remains obscure. Hence, the objective of this research was to probe the potential of HDAC1 in CC radiotherapy sensitivity and its mechanism of action. The expression HDACs and survival analysis of HDAC1 were investigated based on the GEPIA database. Immunohistochemical staining was implemented to detect HDAC1 and Ki-67 expression in tumor tissues. RT-qPCR and Western blot were conducted to assess HDAC1, HIF-1α, VEGFA, along with VEGFR expressions in CC cells and tumor tissues. Cell viability, apoptosis, invasion, migration, along with cell cycle were analyzed by functional assays. Tumor-bearing nude mice model was established, and the tumor weight and volume were determined. HDAC1 was high-expressed in the tumor tissue and CC cells. In vitro, overexpression of HDAC1 suppressed radiotherapy sensitivity in C33A cells, while knockdown of HDAC1 promoted radiotherapy sensitivity in SiHa cells. In vivo, we found that HDAC1 silence hindered tumor growth and cell proliferation and promoted tumor cell apoptosis in nude mice after radiotherapy. In addition, we found that HDAC1 impacted radiotherapy sensitivity by modulating the HIF-1α/VEGF signaling pathway. In conclusion, HDAC1 suppressed the radiotherapy sensitivity of CC via regulating HIF-1α/VEGF signaling pathway, suggesting that HDAC1 may act as a crucial participant in regulating CC radiosensitivity, which may provide a novel method for treating CC.